Article Versions Notes

Olah C, Tschirdewahn S, Hoffmann MJ, Krafft U, Hadaschik B, Nyirady P, Szendröi A, Módos O, Csizmarik A, Kovalszky I, et al. Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients. Diagnostics. 2020; 10(11):864. https://doi.org/10.3390/diagnostics10110864

Olah, Csilla, Stephan Tschirdewahn, Michèle J. Hoffmann, Ulrich Krafft, Boris Hadaschik, Peter Nyirady, Attila Szendröi, Orsolya Módos, Anita Csizmarik, Ilona Kovalszky, and et al. 2020. "Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients" Diagnostics 10, no. 11: 864. https://doi.org/10.3390/diagnostics10110864

Olah, C., Tschirdewahn, S., Hoffmann, M. J., Krafft, U., Hadaschik, B., Nyirady, P., Szendröi, A., Módos, O., Csizmarik, A., Kovalszky, I., Reis, H., & Szarvas, T. (2020). Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients. Diagnostics, 10(11), 864. https://doi.org/10.3390/diagnostics10110864